CTLA4 and non-small cell lung carcinoma: In the last few years, the use of checkpoint inhibitors such as ipilimumab (anti-CTLA4), pembrolizumab (anti-PD1), and nivolumab (anti-PD1) has improved the treatment of certain tumors, like melanoma and non-small-cell lung carcinoma [26].